Clinical Trial

A Study of NX-1607 in Adults With Advanced Malignancies

Name: A Study of NX-1607 in Adults With Advanced Malignancies — clinical trial record (NCT05107674)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

Protocol Amendment History 21 amendments

This ClinicalTrials.gov record has been amended 21 times since 2021-10-25; most recent amendment 2025-09-05.

Trial Details

NCT Number	NCT05107674
Lead Sponsor	Nurix Therapeutics, Inc.
Conditions	Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM) +6 more
Enrollment	345 participants
Start Date	2021-09-29
Primary Completion	2026-08-31 (estimated)
Study Completion	2028-02-28 (estimated)
Updated on ClinicalTrials.gov	2025-09-09